Glenmark Pharmaceuticals U.S. > News

News

Press Releases

Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.

Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL)

February 14, 2025

Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%

February 12, 2025

Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules

January 21, 2025

Glenmark Pharmaceuticals Inc., USA launches Lacosamide Oral Solution, 10 mg/mL

December 16, 2024

Glenmark Pharmaceuticals Inc., USA launches Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution)

November 27, 2024

News

Search Result :-

Is an investigational new drug that has not been approved for commercial distribution in the United States.

February 14, 2025
Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL)

February 12, 2025
Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%

January 21, 2025
Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules

December 16, 2024
Glenmark Pharmaceuticals Inc., USA launches Lacosamide Oral Solution, 10 mg/mL

November 27, 2024
Glenmark Pharmaceuticals Inc., USA launches Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution)

US Media Contact

For media inquiries only, please contact Corporate Communications.
uscomms@glenmarkpharma.com

Investor Relations

For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.

POTASSIUM CHLORIDE EXTENDED RELEASE CAPSULES 750mg RECALL REIMBURSEMENT POLICY

Over-the-counter (OTC)

ACCESSIBLE PRODUCTS

Who We Are

Injectables

OUR GROWING LINE